Brooklyn ImmunoTherapeutics is focused on exploring the role that the human immune system can have in treating patients with cancer and immunologic diseases, both as a single agent and in combination with other therapies. Our most advanced program is studying the safety and efficacy of IRX-2, a human cell-derived (hd) IL-2 therapeutic in patients with head and neck cancer. In a Phase 2a clinical trial in head and neck cancer, IRX-2 was well-tolerated and demonstrated an overall survival benefit. Additional single agent and combination studies are either underway or planned in other solid tumor cancer indications.
View Top Employees from Brooklyn ImmunoTherapeuticsWebsite | http://www.brooklynitx.com |
Employees | 14 (0 on RocketReach) |
Founded | 1994 |
Phone | (212) 582-1199 |
Industry | Biotechnology, Science and Engineering |
Looking for a particular Brooklyn ImmunoTherapeutics employee's phone or email?
Brooklyn ImmunoTherapeutics is based in Brooklyn, New York.